Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Cash, Cash Equivalents and Short-Term Investments (Tables)

Cash, Cash Equivalents and Short-Term Investments (Tables)

6 Months Ended

Jun. 30, 2021

Cash, Cash Equivalents and Short-Term Investments

Schedule of cash, cash equivalents and short-term investments

Cash, cash equivalents and short-term investments consisted of the following (in thousands):


	June 30,		December 31,
	2021		2020
Cash	$	3,746	$	1,988
Money market funds		55,080		19,487
U.S. treasury bills		22,086		10,034
Government-sponsored enterprise securities		11,417		4,920
Corporate bonds and commercial paper		61,058		20,898
	$	153,387	$	57,327
Reported as:
Cash and cash equivalents	$	84,823	$	30,373
Short-term investments		68,564		26,954
	$	153,387	$	57,327

Schedule of cash equivalents and short-term investments including securities with unrealized gains and losses

Cash equivalents and short-term investments include the following securities with gross unrealized gains and losses (in thousands):


			Gross		Gross
	Amortized		Unrealized		Unrealized
June 30, 2021	Cost		Gains		Losses		Fair Value
U.S. treasury bills	$	22,084	$	2	$	—	$	22,086
Government-sponsored enterprise securities		11,416		2		—		11,418
Corporate bonds and commercial paper		61,054		7		(3)		61,058
Total	$	94,554	$	11	$	(3)	$	94,562


			Gross		Gross
	Amortized		Unrealized		Unrealized
December 31, 2020	Cost		Gains		Losses		Fair Value
U.S. treasury bills	$	10,036	$	—	$	(2)	$	10,034
Government-sponsored enterprise securities		4,920		—		—		4,920
Corporate bonds and commercial paper		20,900		—		(2)		20,898
Total	$	35,856	$	—	$	(4)	$	35,852

Schedule of fair value and gross unrealized losses of investments in unrealized loss position

The following table shows the fair value and gross unrealized losses of our investments in individual securities that are in an unrealized loss position, aggregated by investment category (in thousands):


June 30, 2021	Fair Value		Unrealized Losses
Corporate bonds and commercial paper	$	31,634	$	(3)